Evidence map›Paper›PMID 34484186›Full record

ArticleFrontiers in immunology2021

Increased IL-23R

Aziz Farah Izati, Nur Diyana Mohd Shukri, Wan Syamimee Wan Ghazali, Che Maraina Che Hussin, Kah Keng Wong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. The star target in SLE: IL-17.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Aziz Farah IzatiDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Nur Diyana Mohd ShukriDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Wan Syamimee Wan GhazaliHospital Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Che Maraina Che HussinDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Kah Keng WongDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Universiti Sains Malaysia · MYHospital Universiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IL-23/IL-17 axis plays causative roles in the development and progression of systemic lupus erythematosus (SLE). However, it remains unclear if the IL-17RA

Indexed as

AdultAntibodies, AntinuclearC-Reactive ProteinFemaleHumansInterleukin-17Interleukin-23Lupus Erythematosus, SystemicMaleReceptors, InterleukinReceptors, Interleukin-17Severity of Illness IndexT-Lymphocytes, Helper-InducerYoung AdultAntibodies, Antinuclearanti-dsDNA autoantibodyC-Reactive ProteinIL17RA protein, humanIL23R protein, humanInterleukin-17Interleukin-23Receptors, InterleukinReceptors, Interleukin-17IL-17IL-17RAIL-23IL-23/IL-17 axisIL-23RSLEDAI-2Ksystemic lupus erythematosus

Identifiers

PMID34484186
PMCPMC8416093
OpenAlexW3195681925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.